Kiniksa Pharmaceuticals International, plc KNSA Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's stock issuance proceeds?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported stock issuance proceeds of $6.39M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's stock issuance proceeds changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's stock issuance proceeds increased by 100.9% year-over-year, from $3.18M to $6.39M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's stock issuance proceeds?
- Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's stock issuance proceeds has grown at a 62.2% compound annual growth rate (CAGR), from $5.89M to $40.75M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.